What is Insmed Inc (INSM) stock price today?

Insmed Inc (INSM) currently trades at $136.33 per share. The stock has a market capitalization of $29.15B and a P/E ratio of —x.

Is INSM stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Insmed Inc has a Smart Value Score of 39/100 (Grade D), resulting in a "Sell" investment rating. The Piotroski F-Score is 6/9 and Altman Z-Score is -3.77.

What is Insmed Inc's revenue and earnings?

Insmed Inc has trailing twelve-month (TTM) revenue of $606.42M with profit margins of -210.50%. Earnings per share (EPS) is $-6.42.

Is Insmed Inc financially healthy?

Insmed Inc's Piotroski F-Score is 6/9 (moderate financial health). The Altman Z-Score of -3.77 places it in the distress.

INSM

Insmed Inc

NASDAQ: INSM · HEALTHCARE · BIOTECHNOLOGY

$136.33

+0.96% today

Updated 2026-04-30

Market cap

$29.15B

P/E ratio

—

P/S ratio

48.06x

EPS (TTM)

$-6.42

Dividend yield

—

52W range

$64 – $213

Volume

2.3M

Market cap

$29.15B

P/E ratio

—

P/S ratio

48.06x

EPS (TTM)

$-6.42

Dividend yield

—

52W range

$64 – $213

Volume

2.3M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

8.0

Growth

6.3

Quality

2.0

Profitability

5.3

Valuation

C+

6/9

Piotroski F-Score

Moderate

-3.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$212.70

+56.02%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

3 Strong Buy17 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 152.60% QoQ

Risks

- Altman Z -3.77 — distress zone

- Thin margins at -210.50%

- Negative free cash flow $-294.19M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM	2026 (E)
Revenue	$245.36M	$305.21M	$363.71M	$606.42M	$606.42M	$1.7B
Net income	$-481.53M	$-749.57M	$-913.77M	$-1.28B	$-328.49M	—
EPS	—	—	—	—	$-6.42	$-2.93
Free cash flow	$-410.32M	$-549.53M	$-705.80M	$-967.58M	$-294.19M	—
Profit margin	-196.26%	-245.59%	-251.24%	-210.54%	-210.50%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-16	LEWIS, WILLIAM	Sale	6,259	—
2026-04-16	LEWIS, WILLIAM	Sale	4,440	—
2026-04-16	LEWIS, WILLIAM	Buy	6,259	$30.46

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
INSM	$29.15B	39	8.0	2.0	5.3	6.3	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Insmed Inc trades at $136.33. Our Smart Value Score of 39/100 indicates the stock is weak. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of -3.77, it sits in the distress. TTM revenue stands at $606.42M. with profit margins at -210.50%.

Frequently asked questions

What is Insmed Inc's stock price?

Insmed Inc (INSM) trades at $136.33.

Is Insmed Inc overvalued?

Smart Value Score 39/100 (Grade D, Sell).

What is the price target of Insmed Inc (INSM)?

The analyst target price is $212.70, representing +56.0% upside from the current price of $136.33.

What is the future stock price of INSM by 2030?

Our research-backed model estimates Insmed Inc could reach $389.83 by 2030, based on analyst consensus, management guidance, and sector analysis.

What is Insmed Inc's revenue?

TTM revenue is $606.42M.

Piotroski F-Score?

6/9 — moderate financial health.

Altman Z-Score?

-3.77 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio48.06x

ROE-249.30%

Beta1.10

50D MA$148.47

200D MA$154.82

Shares out0.22B

Float0.19B

Short ratio—

Avg volume2.3M

Performance

1 week-0.10%

1 month-18.09%

3 months-13.92%

YTD-22.41%

1 year—

3 years—

5 years—

Compare

INSM vs LLY →INSM vs JNJ →INSM vs ABBV →Stock screener →